news
FEP- Access Plan for Generics and Biosimilars
The FEP regrets the null participation offered by the Administration in the elaboration of the Action Plan to promote the use of generic and biosimilar medicines. The FEP is shown at
- The FEP regrets the null participation offered by the Administration in the elaboration of the Action Plan to promote the use of generic and biosimilar medicines.
- The FEP is in favor of the sustainability of the SNS, but always guaranteeing the quality of care, and respect for the rights of the patient.
Madrid, June 05, 2019. The Spanish Patient Forum (FEP) after having learned through the press of the Action Plan to promote the use of generic and biosimilar medicines, warns that it includes measures that, if applied, would deteriorate the quality of care.
Of particular concern are, among others, the measures related to biological medicines, vital for patients with serious illnesses, since it is essential to assess the individual needs of each patient and the criteria of their doctor to avoid serious risks to health and quality of care. life of these patients.
Read, download and disseminate the Press Release of the Spanish Patient Forum:
Read Related Article:
